Korro Bio, Inc. (KRRO)

↓ Download CSV

CIK 0001703647 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Korro Bio, Inc. reported revenue of $6.39M, up 181.5% from the prior year. The company ran a net loss, with a net margin of -1834.5%. It held $113.51M in total assets against $62.07M in total liabilities.

Key ratios (FY2025)

-1906.4%
Operating margin
-1834.5%
Net margin
-228.0%
Return on equity
+181.5%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$6.39M$2.27M$0
Operating Income-$121.86M-$91.91M-$84.53M-$59.00M-$84.03M-$27.55M-$20.68M-$18.94M-$16.31M
Net Income-$117.26M-$83.58M-$81.17M-$58.03M-$84.69M-$26.51M-$18.75M-$19.17M-$20.24M
EPS (Diluted)$-12.48$-9.37$-53.08$-227.42
Total Assets$113.51M$226.24M$221.66M$73.74M$185.36M$264.72M$223.22M$44.55M
Total Liabilities$62.07M$65.83M$51.75M$8.91M$54.53M$72.23M$55.86M$4.12M
Shareholders' Equity$51.44M$160.41M$169.91M-$99.03M-$42.21M$192.49M$167.36M-$48.28M-$29.64M-$9.66M
Cash & Equivalents$21.82M$55.64M$166.15M$36.33M$79.64M$220.34M$200.16M$42.19M
Operating Cash Flow-$78.56M-$60.07M-$67.28M-$53.65M-$76.06M-$45.19M$34.22M-$17.02M-$14.61M
Capital Expenditures$518.0K$17.90M$7.84M$5.14M$2.91M$6.67M$1.06M$436.0K$1.86M
Shares Outstanding9.42M9.38M8.02M268.5K34.61M33.96M30.84M2.08M